drugset / Trial / NCT06519591
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
NaSingle-groupOpen-labelTreatment
Summary
In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
Timeline
- Start
- 2025-02-25
- Primary completion
- 2026-05
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 20 mg/m2 | Other |
| Subject | S-1 | Small molecule | 80 mg/m2 | Oral |
| Subject | TPX4589 | Other / unclassified | 2 mg/kg | Intravenous |